Yarrow Bioscience prices $150M public offering at $26 per share

Yarrow Bioscience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company, has priced an underwritten public offering of 5,769,231 shares of common stock at $26.00 per share, according to a press release from the company.

The offering is expected to generate approximately $150 million in gross proceeds before underwriting discounts, commissions, and other expenses. The offering is expected to close on September 14, 2026, subject to customary closing conditions.

Yarrow has also granted underwriters a 30-day option to purchase up to an additional 865,384 shares at the public offering price, less underwriting discounts and commissions.

The company said it intends to use the net proceeds to fund research and development expenses for its pipeline and for general corporate purposes, which may include working capital and capital expenditures.

Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering, with LifeSci Capital serving as lead manager.

Yarrow is focused on developing therapies for autoimmune thyroid diseases, including its lead candidate YB-101, a monoclonal antibody targeting the thyroid stimulating hormone receptor.

You May Also Be Interested In

• Yarrow Bioscience launches underwritten public stock offering
• Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch
• Capital Southwest prices $350M notes offering at 6.75% due 2031